Vanda Pharmaceuticals | VNDA - Assets


Vanda Pharmaceuticals reported $488.95M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Akebia Therapeutics USD 376.56M 12.41M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Anika Therapeutics USD 190.27M 833K Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Lexicon Pharmaceuticals USD 184.99M 20.94M Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 12.34B 203M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
Teva Pharmaceutical Industries USD 40.75B 892M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Veracyte USD 1.41B 38.23M Dec/2025